Abstract: Prostate cancer is one of the most common malignancies in males and one of the leading causes of male mortality.Over the past few decades, the treatment landscape of prostate cancer has undergone significant changes.Traditional treatment modalities include surgery, radiotherapy, and hormonotherapy.However, with the in-depth study of the pathogenesis of prostate cancer, nuclear receptortargeted drugs have emerged as an important component in the treatment of prostate cancer.This article reviews the nuclear receptors within prostate cancer as well as the currently developed anti-prostate cancer nuclear receptor-targeted drugs and their resistance mechanisms and safety, along with a prospect of the future development of such drugs.